Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NCT07559123 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT07559123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07559123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 31, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ct, neoadjuvant chemoimmunotherapy, nsclc